Stemina Biomarker Discovery develops and commercializes molecular biomarkers to improve drug safety and human health.
The company opened in November 2007 in Madison, Wisconsin. Stemina’s technology arises from the strategic convergence of two cutting edge technologies, stem cells and metabolomics. Stemina offers two in vitro toxicology assays using these technologies:
(1) devTOX quickPredict is a biomarker-based human in vitro assay for prediction of developmental toxicity that utilizes key biomarkers identified using our metabolomics platform. Customers have the flexibility to use either human embryonic stem (hES) or induced pluripotent stem (iPS) cells .
(2) Cardio quickPredict is an in vitro assay for predicting functional and structural cardiotoxicants based on changes in the metabolism and cell viability of iPS cell-derived cardiomyocytes.
Our new cardiotoxicity assay, Cardio quickPredict, indicates the cardiotoxicity potential of drug candidates and other lead compounds, based on changes in human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) metabolism and viability. Each test article is evaluated at eight concentrations and the potential for cardiotoxicity is predicted based on changes in five metabolites. The assay identifies both functional and structural cardiotoxicants and is complimentary to electrophysiological assessments.
Driven by a need to improve the science and predictive accuracy of known compound and drug candidate toxicity on the developing human embryo, Stemina Biomarker Discovery offers devTOX quickPredict. The assay uses human pluripotent stem (hPS) cells to predict the developmental toxicity potential of a compound based on changes in ornithine and cystine metabolism. The assay is available using human embryonic stem (hES) and induced pluripotent stem (iPS) cells and provides a robust and reproducible, proprietary, all-human system for reducing and replacing animal testing.
The only all-human based screen for assessing the toxicity of drugs and chemical compounds on human development. Stemina's devTOX assays are used by major pharmaceutical, agrochemical, cosmetics and tobacco companies to assess the risk of developmental toxicity. Stemina is an EPA contractor for ToxCast and has extensive data on more than 1,000 compounds tested in its devTOX assays.
devTOX is highly predictive, quick and requires very little compound.
Stemina Biomarker Discovery has not received any reviews.
Stemina Biomarker Discovery has not received any endorsements.